Literature DB >> 6323428

Two classes of cAMP analogs which are selective for the two different cAMP-binding sites of type II protein kinase demonstrate synergism when added together to intact adipocytes.

S J Beebe, R Holloway, S R Rannels, J D Corbin.   

Abstract

Twenty-five cyclic nucleotide analogs were tested individually to act as lipolytic agents and to activate adipocyte protein kinase. The lipolytic potency of individual analogs correlated better with their Ka for protein kinase and their lipophilicity rather than with either parameter alone. Some of the most potent lipolytic analogs had I50 values for the particulate low Km cAMP phosphodiesterase suggesting that their effect was not due to raising endogenous cAMP levels through inhibition of phosphodiesterase. The most potent lipolytic analogs contained a thio moiety at the C-8 or C-6 position. These analogs exhibited concave upward dose-response curves. At high concentrations, some analogs were as effective as optimal concentrations of epinephrine in stimulating glycerol release. The regulatory subunit of protein kinase has two different intrachain cAMP-binding sites and cAMP analogs modified at the C-8 position (C-8 analogs) are generally selective for Site 1 and analogs modified at the C-6 position (C-6 analogs) are generally selective for Site 2 (Rannels, S. R., and Corbin, J. D. (1980) J. Biol. Chem. 255, 7085-7088). Thus, C-8 and C-6 analogs were tested in combination to stimulate lipolysis in intact adipocytes and to activate protein kinase in vitro. Each process was stimulated synergistically by a combination of a C-6 and C-8 analog. Two C-8 analogs or two C-6 analogs added together did not cause synergism of either process. For both lipolysis and protein kinase activation, C-8 thio analogs acted more synergistically than C-8 amino analogs when incubated in combination with C-6 analogs, a characteristic of type II protein kinase. It is concluded that the observed synergism of lipolysis is due to binding of cAMP analogs to both intrachain sites and that it is the type II protein kinase isozyme which is responsible for the lipolytic response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323428

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis.

Authors:  Guillaume Pidoux; Oliwia Witczak; Elisabeth Jarnæss; Linda Myrvold; Henning Urlaub; Anne Jorunn Stokka; Thomas Küntziger; Kjetil Taskén
Journal:  EMBO J       Date:  2011-10-07       Impact factor: 11.598

2.  The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic-AMP-dependent and -independent mechanisms.

Authors:  P Lönnroth; J I Davies; I Lönnroth; U Smith
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

3.  A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

Authors:  Sanjay Goel; Kavita Desai; Manuel Macapinlac; Scott Wadler; Gary Goldberg; Abbie Fields; Mark Einstein; Fabio Volterra; Benny Wong; Russell Martin; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

4.  Insulin inhibition of hepatic cAMP-dependent protein kinase: decreased affinity of protein kinase for cAMP and possible differential regulation of intrachain sites 1 and 2.

Authors:  R A Gabbay; H A Lardy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

6.  Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase.

Authors:  C H Clegg; G G Cadd; G S McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Isoleucine 368 is involved in low-affinity binding of N6-modified cAMP analogues to site B of the regulatory subunit of cAMP-dependent protein kinase I.

Authors:  I Huq; W R Dostmann; D Ogreid
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

8.  Cyclic AMP impairs the rapid effect of insulin to enhance cell-surface insulin-binding capacity in rat adipocytes.

Authors:  J W Eriksson; P Lönnroth; U Smith
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

9.  Effect of phorbol ester and pertussis toxin on the enhancement of noradrenaline release by angiotensin II in mouse atria.

Authors:  I F Musgrave; H Majewski
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

10.  Peroxovanadate but not vanadate exerts insulin-like effects in human adipocytes.

Authors:  P Lönnroth; J W Eriksson; B I Posner; U Smith
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.